Figure 8 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy

Carboplatin modulates the TME via EMT and enhances tumor immunity. A, qPCR analysis of CLDN6, CD44, TGFβ1, and CD3 mRNA expression in huNOG mice bearing NIH:OVCAR-3 tumors quantified at day 3 and 10 after treatment with carboplatin at a dose of 30 mg/kg (blue) or vehicle (red). Quantitative data are presented as the mean ± SD (n = 5, except for vehicle group at day 10 where n = 4). P values were determined by two-tailed Student t test. *, P < 0.05; **, P < 0.01. B–E, Heatmap of nCounter Analysis System results for NIH:OVCAR-3 xenograft tumor in huNOG mice on day 10 after vehicle or carboplatin treatment. The heatmaps show differential expression of genes involved in EMT (B), ECM remodeling and ECM–receptor interaction (C), T-cell function (D), and antigen processing (E) between individual tumors treated with vehicle (n = 4) and carboplatin (n = 5).